|
HY-128583-10mg
|
MedChemexpress LLC
|
G150 [CAS 2369751-30-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-128583-100mg
|
MedChemexpress LLC
|
G150 [CAS 2369751-30-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-128583-25mg
|
MedChemexpress LLC
|
G150 [CAS 2369751-30-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-128583-5mg
|
MedChemexpress LLC
|
G150 [CAS 2369751-30-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-128583-50mg
|
MedChemexpress LLC
|
G150 [CAS 2369751-30-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-128583-1mL
|
MedChemexpress LLC
|
G150 [CAS 2369751-30-2] (10mM in DMSO)
|
|
COVID-19-immunoregulation
|
|
|
HY-N2503-1mg
|
MedChemexpress LLC
|
Ginsenoside F4 [CAS 181225-33-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-N2503-5mg
|
MedChemexpress LLC
|
Ginsenoside F4 [CAS 181225-33-2]
|
|
COVID-19-immunoregulation
|
|
|
HY-112544-10mg
|
MedChemexpress LLC
|
IK1 inhibitor PA-6 [CAS 500715-03-7]
|
|
COVID-19-immunoregulation
|
|
|
HY-112544-25mg
|
MedChemexpress LLC
|
IK1 inhibitor PA-6 [CAS 500715-03-7]
|
|
COVID-19-immunoregulation
|
|
|
HY-112544-5mg
|
MedChemexpress LLC
|
IK1 inhibitor PA-6 [CAS 500715-03-7]
|
|
COVID-19-immunoregulation
|
|
|
HY-112544-50mg
|
MedChemexpress LLC
|
IK1 inhibitor PA-6 [CAS 500715-03-7]
|
|
COVID-19-immunoregulation
|
|
|
HY-112544-1mL
|
MedChemexpress LLC
|
IK1 inhibitor PA-6 [CAS 500715-03-7] (10mM in DMSO)
|
|
COVID-19-immunoregulation
|
|
|
HY-N0774-1mg
|
MedChemexpress LLC
|
Isofraxidin [CAS 486-21-5]
|
|
COVID-19-immunoregulation
|
|
|
HY-N0774-10mg
|
MedChemexpress LLC
|
Isofraxidin [CAS 486-21-5]
|
|
COVID-19-immunoregulation
|
|
|
HY-N0774-20mg
|
MedChemexpress LLC
|
Isofraxidin [CAS 486-21-5]
|
|
COVID-19-immunoregulation
|
|
|
HY-N0774-5mg
|
MedChemexpress LLC
|
Isofraxidin [CAS 486-21-5]
|
|
COVID-19-immunoregulation
|
|
|
HY-N0774-1mL
|
MedChemexpress LLC
|
Isofraxidin [CAS 486-21-5] (10mM in DMSO)
|
|
COVID-19-immunoregulation
|
|
|
HY-N10534-1mg
|
MedChemexpress LLC
|
Lewis X trisaccharide [CAS 71208-06-5]
|
|
COVID-19-immunoregulation
|
|
